Systematic reviews and meta-analysesEffects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis
Section snippets
Methods
The study was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.9
Study Characteristics
Figure 1 depicts the study selection process. Of the 3478 references identified from database searches, 235 articles were selected for full text review. After reviewing the full text, 154 articles were excluded. Of the remaining 81 articles, 46 articles were excluded for the reasons detailed in Supplementary Table 1, and 35 studies5, 6, 7, 8, 12, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 that reported results in 6790
Discussion
Several observational studies and randomized controlled trials have examined the association between concurrent use of immunomodulators and ADAs formation in treatment of patients with IBD. To the best of our knowledge, the present study is the first meta-analysis to investigate the pooled impact of concomitant immunomodulators on immunogenicity of all approved anti-TNFs including IFX, adalimumab, certolizumab, and golimumab in patients with IBD. Overall, patients with IBD who are on anti-TNF-α
References (54)
- et al.
Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects
J Crohns Colitis
(2010) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial
Gastroenterology
(2003) - et al.
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
Clin Gastroenterol Hepatol
(2004) - et al.
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
Gastroenterology
(2008) - et al.
Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment
J Crohns Colitis
(2014) - et al.
Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials
Clin Ther
(2011) - et al.
Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis
Am J Gastroenterol
(2010) - et al.
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
Gut
(2010) - et al.
Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators
Gut
(2012)
Infliximab, azathioprine, or combination therapy for Crohn's disease
N Engl J Med
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Clin Gastroenterol Hepatol
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
Inflamm Bowel Dis
Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment
J Gastroenterol
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Ann Intern Med
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
BMJ
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Eur J Epidemiol
Infliximab maintenance therapy for fistulizing Crohn's disease
N Engl J Med
Analysis of clinical trial outcomes: some comments on subgroup analyses
Control Clin Trials
Analysis of clinical trial outcomes: alternative approaches to subgroup analysis
Control Clin Trials
Defining disease severity in inflammatory bowel diseases: current and future directions
Clin Gastroenterol Hepatol
Understanding heterogeneity in meta-analysis: the role of meta-regression
Int J Clin Pract
Bias in meta-analysis detected by a simple, graphical test
BMJ
Estimating the mean and variance from the median, range, and the size of a sample
BMC Med Res Methodol
Quantifying heterogeneity in a meta-analysis
Stat Med
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
N Engl J Med
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
J Pediatr Gastroenterol Nutr
Cited by (48)
The efficacy of adalimumab in treating patients with central multifocal choroiditis
2020, American Journal of Ophthalmology Case ReportsCitation Excerpt :In most cases, though not all, adalimumab was reported to be effective, which is in line with the results of our study. All patients were concomitantly treated with IMT for synergistic effect as well as prohibition of the formation of anti-drug antibodies to adalimumab, though literature is conflicting concerning the latter indication.27 In our study, intravitreal anti-VEGF injections were extended and discontinued after the initiation of treatment with adalimumab.
AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis
2020, GastroenterologyCitation Excerpt :First, immunomodulators have their independent efficacy in patients with UC, which may add to the benefits observed with biologics. Second, immunomodulators have been consistently shown to decrease the risk of immunogenicity to biologic agents and may increase trough concentrations of these agents.98 However, direct comparison with drugs other than infliximab are lacking, and the rates of immunogenicity with adalimumab, golimumab, vedolizumab, and ustekinumab are lower than with infliximab.
Chinese clinical practice guideline on the management of Crohn′s disease (2023, Guangzhou)
2024, Chinese Journal of Inflammatory Bowel DiseasesControversies in the management of anti-TNF therapy in patients with Crohn's disease: a Delphi consensus
2024, BMJ Open GastroenterologyMethotrexate is the re-discovered drug for Crohn’s disease
2024, Gastroenterologie a HepatologieOral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature
2023, Current Rheumatology Reports
Conflicts of interest The authors disclose no conflicts.
Funding This study was financially supported by the National Natural Science Foundation of China (grants 81470821, 81670498, 81630018, and 81500501).
- a
Authors share co-first authorship.